1. O'Duffy JD. Behçet's disease. Curr Opin Rheumatol 1994;6:39-43.PMID:
8031678.
2. Kaklamani VG, Vaiopoulos G, Kaklamanis PG. Behçet's disease. Semin Arthritis Rheum 1998;27:197-217.PMID:
9514126.
3. Sakane T, Takeno M, Suzuki N, Inaba G. Behçet's disease. N Engl J Med 1999;341:1284-1291.PMID:
10528040.
4. Baba S, Maruta M, Ando K, Teramoto T, Endo I. Intestinal Behçet's disease: report of five cases. Dis Colon Rectum 1976;19:428-440.PMID:
939158.
5. Kasahara Y, Tanaka S, Nishino M, Umemura H, Shiraha S, Kuyama T. Intestinal involvement in Behçet's disease: review of 136 surgical cases in the Japanese literature. Dis Colon Rectum 1981;24:103-106.PMID:
7215071.
6. Bayraktar Y, Ozaslan E, Van Thiel DH. Gastrointestinal manifestations of Behcet's disease. J Clin Gastroenterol 2000;30:144-154.PMID:
10730919.
7. Grigg EL, Kane S, Katz S. Mimicry and deception in inflammatory bowel disease and intestinal Behçet disease. Gastroenterol Hepatol (N Y) 2012;8:103-112.PMID:
22485077.
8. Kim DH, Cheon JH. Intestinal Behçet's disease: a true inflammatory bowel disease or merely an intestinal complication of systemic vasculitis? Yonsei Med J 2016;57:22-32.PMID:
26632379.
9. Yang SK. Intestinal Behcet's disease. Intest Res 2005;3:1-10.
10. Kim SU, Cheon JH, Lim JS, et al. Massive gastrointestinal bleeding due to aneurysmal rupture of ileo-colic artery in a patient with Behcet's disease. Korean J Gastroenterol 2007;49:400-404.PMID:
17641560.
11. Jung YS, Cheon JH, Park SJ, Hong SP, Kim TI, Kim WH. Long-term clinical outcomes of Crohn's disease and intestinal Behcet's disease. Inflamm Bowel Dis 2013;19:99-105.PMID:
22508364.
12. Lakhanpal S, Tani K, Lie JT, Katoh K, Ishigatsubo Y, Ohokubo T. Pathologic features of Behçet's syndrome: a review of Japanese autopsy registry data. Hum Pathol 1985;16:790-795.PMID:
4018777.
13. Cheon JH, Shin SJ, Kim SW, et al. Diagnosis of intestinal Behçet's disease. Korean J Gastroenterol 2009;53:187-193.PMID:
19835220.
14. Cheon JH, Kim WH. An update on the diagnosis, treatment, and prognosis of intestinal Behçet's disease. Curr Opin Rheumatol 2015;27:24-31.PMID:
25405821.
15. Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease. Lancet 1990;335:1078-1080.PMID:
1970380.
16. Mizushima Y, Inaba G, Mimura Y, Ono S. Diagnostic criteria for Behçet's disease in 1987, and guidelines for treating Behçet's disease. Saishin Igaku 1988;43:382-391.
17. Lee CR, Kim WH, Cho YS, et al. Colonoscopic findings in intestinal Behçet's disease. Inflamm Bowel Dis 2001;7:243-249.PMID:
11515851.
18. Kim JS, Lim SH, Choi IJ, et al. Prediction of the clinical course of Behçet's colitis according to macroscopic classification by colonoscopy. Endoscopy 2000;32:635-640.PMID:
10935793.
19. Shepherd NA. Pathological mimics of chronic inflammatory bowel disease. J Clin Pathol 1991;44:726-733.PMID:
1918397.
20. Ebert EC. Gastrointestinal manifestations of Behçet's disease. Dig Dis Sci 2009;54:201-207.PMID:
18594975.
21. Kobayashi K, Ueno F, Bito S, et al. Development of consensus statements for the diagnosis and management of intestinal Behçet’s disease using a modified Delphi approach. J Gastroenterol 2007;42:737-745.PMID:
17876543.
22. Cheon JH, Celik AF, Kim WH. Behçet's disease: gastrointestinal involvement. In: Yazici Y, Yazici H. eds. Behçet's syndrome. New York: Springer, 2010:165-188.
23. Lee SK, Kim BK, Kim TI, Kim WH. Differential diagnosis of intestinal Behçet's disease and Crohn's disease by colonoscopic findings. Endoscopy 2009;41:9-16.PMID:
19160153.
24. Lee YJ, Yang SK, Byeon JS, et al. Analysis of colonoscopic findings in the differential diagnosis between intestinal tuberculosis and Crohn's disease. Endoscopy 2006;38:592-597.PMID:
16673312.
25. O'Duffy JD. Vasculitis in Behçet's disease. Rheum Dis Clin North Am 1990;16:423-431.PMID:
2189158.
26. Shin SJ, Lee SK, Kim TI, et al. Chronological changes in the systemic manifestations of intestinal Behcet's disease and their significance in diagnosis. Int J Colorectal Dis 2010;25:1371-1376.PMID:
20533055.
27. Muto T. Historical review of so called “simple ulcer” of the intestine. Stomach Intestine 1979;14:739-748.
28. Jung HC, Rhee PL, Song IS, Choi KW, Kim CY. Temporal changes in the clinical type or diagnosis of Behçet's colitis in patients with aphthoid or punched-out colonic ulcerations. J Korean Med Sci 1991;6:313-318.PMID:
1844639.
29. Cheon JH, Kim ES, Shin SJ, et al. Development and validation of novel diagnostic criteria for intestinal Behçet's disease in Korean patients with ileocolonic ulcers. Am J Gastroenterol 2009;104:2492-2499.PMID:
19532129.
30. Jung YS, Cheon JH, Park SJ, Hong SP, Kim TI, Kim WH. Clinical course of intestinal Behcet's disease during the first five years. Dig Dis Sci 2013;58:496-503.PMID:
22899244.
31. Cheon JH, Kim WH. Recent advances of endoscopy in inflammatory bowel diseases. Gut Liver 2007;1:118-125.PMID:
20485627.
32. Lee HJ, Kim YN, Jang HW, et al. Correlations between endoscopic and clinical disease activity indices in intestinal Behcet's disease. World J Gastroenterol 2012;18:5771-5778.PMID:
23155319.
33. Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut 2007;56:453-455.PMID:
17369375.
34. Frøslie KF, Jahnsen J, Moum BA, Vatn MH. IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007;133:412-422.PMID:
17681162.
35. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-2476.PMID:
16339095.
36. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009;15:1295-1301.PMID:
19340881.
37. Yim SM, Kim DH, Lee HJ, et al. Mucosal healing predicts the long-term prognosis of intestinal Behçet's disease. Dig Dis Sci 2014;59:2529-2535.PMID:
24838499.
38. De Cruz P, Kamm MA, Hamilton AL, et al. Crohn's disease management after intestinal resection: a randomised trial. Lancet 2015;385:1406-1417.PMID:
25542620.
39. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006;55:426-431.PMID:
16474109.
40. Sands BE. Biomarkers of inflammation in inflammatory bowel disease. Gastroenterology 2015;149:1275-1285.e2.PMID:
26166315.
41. Müftüoğlu AU, Yazici H, Yurdakul S, et al. Behçet's disease: relation of serum C-reactive protein and erythrocyte sedimentation rates to disease activity. Int J Dermatol 1986;25:235-239.PMID:
3710672.
42. Coskun B, Saral Y, Gödekmerdan A, Erden I, Coskun N. Activation markers in Behçet's disease. Skinmed 2005;4:282-286.PMID:
16282749.
43. Jung YS, Hong SP, Kim TI, Kim WH, Cheon JH. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet disease. J Clin Gastroenterol 2012;46:e38-e45.PMID:
22298088.
44. Jung YS, Yoon JY, Lee JH, et al. Prognostic factors and long-term clinical outcomes for surgical patients with intestinal Behcet's disease. Inflamm Bowel Dis 2011;17:1594-1602.PMID:
21674717.
45. Choi CH, Kim TI, Kim BC, et al. Anti-Saccharomyces cerevisiae antibody in intestinal Behçet's disease patients: relation to clinical course. Dis Colon Rectum 2006;49:1849-1859.PMID:
17080284.
46. Shin SJ, Kim BC, Kim TI, Lee SK, Lee KH, Kim WH. Anti-alpha-enolase antibody as a serologic marker and its correlation with disease severity in intestinal Behçet's disease. Dig Dis Sci 2011;56:812-818.PMID:
20632102.
47. Bouchon A, Dietrich J, Colonna M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol 2000;164:4991-4995.PMID:
10799849.
48. Jung YS, Kim SW, Yoon JY, et al. Expression of a soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) correlates with clinical disease activity in intestinal Behcet's disease. Inflamm Bowel Dis 2011;17:2130-2137.PMID:
21910175.
49. Lee HW, Chung SH, Moon CM, et al. The correlation of serum IL-12B expression with disease activity in patients with inflammatory bowel disease. Medicine (Baltimore) 2016;95:e3772PMID:
10.1097/MD.0000000000003772. PMID:
27281077.
51. Wei SC. Could fecal calprotectin enter mainstream use for diagnosing and monitoring inflammatory bowel disease? Intest Res 2016;14:293-294.PMID:
27799878.
52. Kim DH, Park Y, Kim B, et al. Fecal calprotectin as a non-invasive biomarker for intestinal involvement of Behçet's disease. J Gastroenterol Hepatol 2017;32:595-601.PMID:
27521492.
53. Cheon JH, Han DS, Park JY, et al. Development, validation, and responsiveness of a novel disease activity index for intestinal Behçet's disease. Inflamm Bowel Dis 2011;17:605-613.PMID:
20848515.
54. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-444.PMID:
1248701.
55. Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007;133:423-432.PMID:
17681163.
56. Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease: a prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Gut 1994;35:231-235.PMID:
7508411.
57. Kim ES, Chen M, Lee J, Lee CK, Kim YS. Diagnosis of inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2(nd) Asian Organization for Crohn's and Colitis (AOCC) meeting in Seoul. Intest Res 2016;14:224-230.PMID:
27433144.